Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90106 | 0.85 | CA1 (0.45) | AAK1CA1CA2CA7CAPN1 | |
| SCHEMBL89642 | 0.85 | CA1 (0.45) | AAK1CA1CA2CA7CAPN1 | |
| SCHEMBL19227630 | 0.85 | CA1 (0.58) | AAK1CA1CA2CA7CAPN1 | |
| SCHEMBL1989347 | 0.84 | CA1 (0.42) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL14923598 | 0.84 | AAK1 (0.53) | AAK1CA1CA2CA7CAPN1 | |
| SCHEMBL14175255 | 0.84 | AAK1 (0.53) | AAK1CA1CA2CA7CAPN1 | |
| SCHEMBL1989346 | 0.84 | CA1 (0.42) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL3375872 | 0.84 | AAK1 (0.53) | AAK1CA1CA2CA7CAPN1 | |
| SCHEMBL5262474 | 0.83 | CA1 (0.53) | AAK1CA1CA2CA7CAPN1 | |
| SCHEMBL15250454 | 0.83 | CA1 (0.53) | AAK1CA1CA2CA7CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527338-B1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL) -3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| EP-2181105-B1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2015-04-29 | — | — | EP | disclosed |
| US-8497286-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8383650-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-8383650-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20130005770-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2013-01-03 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2009000811-A1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
| US-20080319018-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080319018-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | AAK1 3567/4885CA1 2037/4885CA2 562/4885 |
| US-20080319018-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | AAK1 4504/4885CA1 1553/4885CA2 458/4885 |
| US-20130005770-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | AAK1 4504/4885CA1 1553/4885CA2 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.